Format

Send to

Choose Destination
Hum Mol Genet. 2015 May 15;24(10):2764-70. doi: 10.1093/hmg/ddv037. Epub 2015 Feb 4.

The clinical presentation of Marfan syndrome is modulated by expression of wild-type FBN1 allele.

Author information

1
Laboratory for Vascular Translational Science, INSERM U1148, 75018 Paris, France.
2
Laboratory for Vascular Translational Science, INSERM U1148, 75018 Paris, France, Département de Génétique and.
3
Laboratoire de Biotechnologies Cellulaires, Groupement Hospitalier Est, Hospices Civils de Lyon, 69008 Lyon, France and.
4
Service de Pédiatrie, Hôpital Ambroise Paré, Assistance Publique Hôpitaux de Paris, 92100 Boulogne, France.
5
Laboratory for Vascular Translational Science, INSERM U1148, 75018 Paris, France, National Reference Centre for Marfan Syndrome and Related Disorders, Service de Cardiologie, Centre Hospitalier Universitaire Xavier Bichat, Assistance Publique Hôpitaux de Paris, 75018 Paris, France.
6
National Reference Centre for Marfan Syndrome and Related Disorders, Service de Cardiologie, Centre Hospitalier Universitaire Xavier Bichat, Assistance Publique Hôpitaux de Paris, 75018 Paris, France.
7
National Reference Centre for Marfan Syndrome and Related Disorders, Service de Cardiologie, Centre Hospitalier Universitaire Xavier Bichat, Assistance Publique Hôpitaux de Paris, 75018 Paris, France, chantal.stheneur@apr.aphp.fr.

Abstract

Marfan syndrome is an autosomal dominant disorder mainly caused by mutations within FBN1 gene. The disease displays large variability in age of onset or severity and very poor phenotype/genotype correlations have been demonstrated. We investigated the hypothesis that phenotype severity could be related to the variable expression level of fibrillin-1 (FBN1) synthesized from the wild-type (WT) allele. Quantitative reverse-transcription and polymerase chain reaction was used to evaluate FBN1 levels in skin fibroblasts from 80 Marfan patients with premature termination codons and in skin fibroblasts from 80 controls. Results in controls showed a 3.9-fold variation in FBN1 mRNA synthesis level between subjects. A similar 4.4-fold variation was found in the Marfan population, but the mean level of FBN1 mRNA was a half of the control population. Differential allelic expression analysis in Marfan fibroblasts showed that over 90% of FBN1 mRNA was transcribed from the wild allele and the mutated allele was not detected. In the control population, independently of the expression level of FBN1, we observed steady-state equilibrium between the two allelic-mRNAs suggesting that FBN1 expression mainly depends on trans-acting regulators. Finally, we show that a low level of residual WT FBN1 mRNA accounts for a high risk of ectopia lentis and pectus abnormality and tends to increase the risk of aortic dilatation.

PMID:
25652400
DOI:
10.1093/hmg/ddv037
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center